This case is the first to demonstrate the successful treatment of a metastatic melanoma patient with concurrent CLL/SLL using lymphodepleting chemotherapy followed by unselected TIL and interleukin-2. This evidence concerns the gene IL2 and B-cell chronic lymphocytic leukemia.